Additionally, we found increases in CTLA-4, TIM-3 and CD137 expression among T cells in the tumor compared to PBMCs, suggesting a complex immunoregulatory network inside the tumor with several possibilities for therapeutical interference. The gene discussed is HAVCR2; the disease is neoplasm.